News

August 2nd, 2018 | Clinical ConnectionsPharmacy Pearls

Starting at the end of August, AHP’s clinical pharmacists will be offering on-site provider visits to provide up-to-date, objective evidence focusing on outpatient medication management topics. These visits are: • Typically 10-15 minutes, based on providers’ schedules • 1:1 or in group provider settings, whichever is more convenient • Intended to be interactive- the clinical…

Read More ›

July 20th, 2018 | Pharmacy Pearls

This edition of Pharmacy Pearls discusses some of the nuances associated with selecting a urinary antispasmodic for incontinence, including a brief comparison of safety, tolerability, and approximate cost. Additionally, we are featuring a new section of Pharmacy Pearls called “Clinical Pharmacist Medication Management Highlight.” This will be a section where we gather examples from clinical…

Read More ›

May 17th, 2018 | Pharmacy Pearls

This edition of Pharmacy Pearls presents an equivalent dose chart for those providers wishing to switch patients from Lyrica to gabapentin to save patients money. Additionally, it contains information about the incidence of reactions to the Shingrix vaccine, information about the costs of different testosterone dosage forms, and an update about a new follow-on rapid-acting…

Read More ›

April 2nd, 2018 | Pharmacy Pearls

As discussed in the last Pharmacy Pearls “Less Expensive Inhaler Now Available,” switching patients to RespiClick will help AHP realize significant savings as well as help patients with their out-of-pocket costs. The patient education handout below can be provided to patients making the switch to ensure that they use their new inhaler correctly.

March 5th, 2018 | Network NewsNewsPharmacy Pearls

Opportunity to offer a less expensive generic maintenance inhaler to patients: The first generic ICS/LABA inhaler, fluticasone/salmeterol RespiClick®, was FDA approved in 2017. Current review of inhaler prescribing suggests the potential to realize a minimum of $900,000 savings across the network in 2018 by switching 25% of brand ICS/LABA inhalers to the generic product. Additionally,…

Read More ›

January 11th, 2018 | NewsPharmacy Pearls

In light of the recent uptick in flu cases, please see the bulletin below regarding treatment and post-exposure prophylaxis. Prior to prescribing to lower risk patients, we encourage you to weigh the benefit of a 12 – 24 hour reduction in symptoms with the risks of GI intolerance and potential for antiviral resistance. Stay healthy!…

Read More ›

November 13th, 2017 | NewsPharmacy Pearls

This edition of Pharmacy Pearls is focused on the 2017-2018 influenza season. Prepared by Saloni Patel, PharmD, the Infectious Diseases PGY2 Pharmacy Resident at URMC, the newsletter details the available vaccine formulations and reviews information on Tamiflu, vaccination in older adults, high-dose vaccines, and vaccine immunity. As always, we are available for any medication-related questions…

Read More ›

September 11th, 2017 | NewsPharmacy Pearls

This edition of Pharmacy Pearls provides a brief introduction to the new Clinical Pharmacy Team at AHP as well as an overview of the medications approved for long-term weight loss with risks/benefits and guidance as to when you might choose one over another. There is also a section addressing the incredible cost difference between certain…

Read More ›

September 14th, 2016 | Pharmacy Pearls
May 31st, 2016 | Pharmacy Pearls

Welcome to the first installment of the Pharmacy Pearls newsletter. This edition discusses the evidence behind some recently raised concerns surrounding PPI use along with guidance for tapering to minimize rebound hypersecretion. We hope you find this useful in your daily practice. Suggestions or comments may be directed to Jineane Venci, clinical pharmacist at [email protected]